Arpa C, Khalid H, Chandra S, et al. - Researchers conducted this retrospective cohort study to characterize 10-year trends in visual outcomes, anatomical outcomes and treatment burden of patients receiving antivascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD). The sample consisted of 103 patients. Kaplan-Meier analyses showed the median time to best-corrected visual acuity (BCVA) reaching ≤ 35 and ≥ 70 letters were 37.8 and 8.3 months after starting anti-VEGF therapy, respectively. The importance of long-term visual prognosis is illustrated by the chronicity of nAMD disease and its management. The analyses indicate that one in five patients will retain good vision (BCVA ≥70 ETDRS letters) in the first-affected eye at 10 years after commencing anti-VEGF treatment; yet, one in two patients will have good vision in their better-seeing eye. In addition, the data indicate that early treatment of nAMD is linked to better visual outcomes.